May 2017 $4 M Private placement after listing $2 to $10 million 4
Nile Therapeutics, Inc.: Private sale, May 2017 × Investors in this round 4 investors had bought by the notice of May 19, 2017: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anthony Bergmann · Executive Officer Deborah Ascheim · Executive Officer Karen Krasney · Executive Officer Leland Gershell · Executive Officer Linda Marban · Executive Officer, Director Rachel Smith · Executive Officer David Musket · Director Earl Collier · Director Frank Litvack · Director George Dunbar · Director Joshua Kazam · Director Louis Manzo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Linda Marban, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC .
equity SEC Feb 2015 $7 M Private placement after listing $2 to $10 million 8
Nile Therapeutics, Inc.: Private sale, Feb 2015 × Investors in this round 8 investors had bought by the notice of Feb 19, 2015: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $364,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Hamer · Executive Officer Anthony Bergmann · Executive Officer Karen Krasney · Executive Officer Linda Marban · Executive Officer, Director · President and Chief Executive Officer, Director Rachel Smith · Executive Officer David Musket · Director Earl Collier, Jr. · Director Frank Litvack · Director George Dunbar · Director Gregory Schafer · Director Joshua Kazam · Director Louis Grasmick · Director Louis Manzo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in NJ, NY SC&H Capital (CRD 148291) · Sparks, Maryland Sold in MD Signed by Linda Marban, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 19, 2015. Read the notice at the SEC .
equity SEC Jan 2015 $10 M Private placement after listing $10 to $50 million 39
Nile Therapeutics, Inc.: Private sale, Jan 2015 × Investors in this round 39 investors had bought by the notice of Feb 3, 2015: 39 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $126,900
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Hamer · Executive Officer Anthony Bergmann · Executive Officer Karen Krasney · Executive Officer Linda Marban · Executive Officer, Director · President and Chief Executive Officer, Director Rachel Smith · Executive Officer David Musket · Director Earl Collier, Jr. · Director Frank Litvack · Director George Dunbar · Director Gregory Schafer · Director Joshua Kazam · Director Louis Grasmick · Director Louis Manzo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in IL, NY SC&H Capital (CRD 148291) · Sparks, Maryland Sold in MD Signed by Linda Marban, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2015. Read the notice at the SEC .
equity SEC Nov 2013 $26 M Private placement after listing $10 to $50 million 34
Nile Therapeutics, Inc.: Private sale, Nov 2013 × Investors in this round 34 investors had bought by the notice of Dec 5, 2013: 27 accredited, 7 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $26 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Hamer · Executive Officer Anthony Bergmann · Executive Officer Anthony Davies · Executive Officer Karen Krasney · Executive Officer Linda Marban · Executive Officer, Director Rachel Smith · Executive Officer David Musket · Director Earl Collier, Jr. · Director Frank Litvack · Director George Dunbar · Director Gregory Schafer · Director Joshua Kazam · Director Louis Grasmick · Director Louis Manzo · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Not applicable.”On the amounts: “Total shares issued pursuant to the terms of the merger agreement, multiplied by the price of the common stock ($2.50 per share after the reverse stock split) on the date of closing (11/20/2013).”On a merger: “Common stock issued in connection with the merger of a wholly-owned subsidiary of Nile Therapeutics, Inc. with and into Capricor, Inc.”Signed by Linda Marban, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 5, 2013. Read the notice at the SEC .
equity SEC Jun 2011 $3 M No. 2 $2 to $10 million 6
Nile Therapeutics, Inc.: Raise no. 2, Jun 2011 × Investors in this round 6 investors had bought by the notice of Jun 27, 2011: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $175,000
Finders' fees none
Paid to its own people $307,500 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Daron A Evans · Executive Officer Hsiao D. Lieu · Executive Officer Joshua A Kazam · Executive Officer, Director Richard B. Brewer · Executive Officer, Director Arie S. Belldegrun · Director Frank M. Litvack · Director Gregory W. Schafer · Director Paul A. Mieyal · Director Pedro S. Granadillo · Director Peter M. Kash · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, New York Sold in CA, NJ, NY Ladenburg Thalmann & Co., Inc. (CRD 505) · broker-dealer Ladenburg Thalmann & Co., Inc. (CRD 505) · New York, New York Sold in NY Remarks in the notice On fees: “Plus Warrants to purchase 250,000 shares”On the use of proceeds: “Represents payments of salaries to Executive Officers”Signed by Daron Evans, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 27, 2011. Read the notice at the SEC .
equity, options SEC Jul 2009 $2 M No. 1 $2 to $10 million 24
Nile Therapeutics, Inc.: Raise no. 1, Jul 2009 × Investors in this round 24 investors had bought by the notice of Jul 15, 2009: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daron Evans · Executive Officer David M. Tanen · Executive Officer, Director Joshua A. Kazam · Executive Officer, Director Gregory W. Schafer · Director Paul A. Mieyal, Ph.D. · Director Pedro Granadillo · Director Peter M. Kash · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, Ny Sold in no state named Remarks in the notice On fees: “Riverbank was not paid a cash commission for its services, but did receive five-year warrants to purchase 218,300 shares of Company common stock at an exercise price of $1.375. Also, a non-accountable exp. allowance of $50,000 was paid.”On the amounts: “The offering is being made simultaneously to U.S. and foreign investors.”Signed by Daron Evans, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 15, 2009. Read the notice at the SEC .
equity, options SEC